• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Sanofi-Aventis ADR

Sanofi-Aventis ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014

    Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014

  2. Where Are the Opportunities in U.S. Health Care?

    As the sector has continued to best the broader market, a look both at the dynamics that would drive further outperformance by the sector and at funds that investors can use to tap those themes.

  3. Rentrak Announces Official Worldwide Box Office Results for Weekend of August 24, 2014

    Rentrak Announces Official Worldwide Box Office Results for Weekend of August 24, 2014

  4. A Shift in Health-Care M&A Activity

    Recent deals have been driven more by tax strategies than therapeutic synergies.

  5. Rentrak Announces Official Worldwide Box Office Results for Weekend of August 17, 2014

    Rentrak Announces Official Worldwide Box Office Results for Weekend of August 17, 2014

  6. FDA Approves Genzyme’s Cerdelga™ (eliglustat) Capsules

    FDA Approves Genzyme’s Cerdelga™ (eliglustat) Capsules

  7. Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanofi to Redefine Companion Diagnostics for Oncology

    Illumina Announces Strategic Partnerships with AstraZeneca, Janssen and Sanofi to Redefine Companion Diagnostics for Oncology

  8. Rentrak Announces Worldwide Box Office Results for Weekend of August 10, 2014

    Rentrak Announces Worldwide Box Office Results for Weekend of August 10, 2014

  9. Sanofi, MannKind to commercialize Afrezza insulin therapy

    Sanofi, MannKind to commercialize Afrezza insulin therapy

  10. UPDATE: Priceline, Dean Foods are stocks to watch Monday

    UPDATE: Priceline, Dean Foods are stocks to watch Monday

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.